Reminder: Roche Virtual Event – Key ophthalmology data presented at the Angiogenesis 2023 Meeting
Monday 13th February 2023 We are pleased to invite investors and analysts to participate in our virtual event onMonday, 13February 2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February. 16:30 – 18:00 CET / 15:30– 17:00 GMT10:30 – 12:00pm EST / 7:30 –9:00 am PST AgendaWelcome -BrunoEschli, Head of Investor RelationsRoche ophthalmology strategy -Nilesh Mehta, Global Franchise Head of OphthalmologyRoche ophthalmology pipeline -ChristopherBrittain, Vice President and Global Head of Ophthalmology Product DevelopmentKey data present...
Source: Roche Investor Update - February 6, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche ’s Corporate Executive Committee
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments:Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based in South San Francisco, will become a member of the enlarged Corporate Executive Committee. Both will report to the Roche Group CE...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Investor Update - February 1, 2023 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s Full Year Results 2022 Presentation
Roche will publish its Full Year Results for 2022 prior to the opening of the Swiss Stock Exchange on Thursday, 2 February 2023. 07:00 CET / 06:00 GMT / 01:00 AM EST / 10:00 PM PST (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here The webinar will start with presentations by senior management,followed by a Q&A session.Presenters:Severin Schwan, CEO Roche GroupThomas Schinecker, CEO Roche Pharmaceuticals ad interimMatt Sause, CEO Roche DiagnosticsAlan Hippe, Chief Financial and IT Officer We would lik...
Source: Roche Investor Update - January 26, 2023 Category: Pharmaceuticals Source Type: news
Invitation: Roche Virtual Event – Key ophthalmology data presented at the Angiogenesis 2023 Meeting
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 13February 2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February. 16:30 – 18:00 CET / 15:30– 17:00 GMT10:30 – 12:00pm EST / 7:30 –9:00 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event.>click here Access to virtual event (pre-registration required)Please pre-register for our webinarhere*. ...
Source: Roche Investor Update - January 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
Save The Date: Roche Virtual Event – Key ophthalmology data presented at the Angiogenesis 2023 Meeting
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 13February 2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February. 16:30 – 18:00 CET / 15:30– 17:00 GMT10:30 – 12:00pm EST / 7:30 –9:00 am PST An invitation with the detailed programme and registration link will follow soon. Best regards, Bruno EschliHead of Investor Relations Loren KalmHead of Investor Relations, North AmericaRoche Investor Relations Dr. BrunoEschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabin...
Source: Roche Investor Update - January 13, 2023 Category: Pharmaceuticals Source Type: news
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Roche ’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
If approved,glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphomaResults from the pivotal phase I/II NP30179 study showedglofitamab induced durable response rates in people with heavily pre-treated large B-cell lymphoma, with 40% achieving a complete responseGlofitamab is part of Roche ’s industry-leading portfolio of T-cell engaging bispecific antibodies, which also includes the newly FDA-approved first-in-classLunsumio to treat follicular lymphomaBasel, 6 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announc...
Source: Roche Investor Update - January 6, 2023 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma
The objective response rate is the combination of complete response (CR) rate (a disappearance of all signs and symptoms of cancer) and partial response rate (a decrease in the amount of cancer in the body). The median duration of response among those who responded was almost two years (22.8 months [95% CI: 10-not reached]). A CR was achieved in 60% of patients (54/90 [95% CI: 49-70]). Among 218 patients with haematologic malignancies who received Lunsumio at the recommended dose, the most common adverse event (AE) was cytokine release syndrome (CRS; 39%), which can be severe and life-threatening. The median duration of CR...
Source: Roche Investor Update - December 23, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s Full Year Results 2022 Presentation
Roche will publish its Full Year Results for 2022 prior to the opening of the Swiss Stock Exchange onThursday, 2 February 2023. 07:00 CET / 06:00 GMT / 01:00 AM EST / 10:00 PM PST (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here 14:00 – 16:00 CET / 13:00 – 15:00 GMT08:00 – 10:00 AM EST / 05:00 - 07:00 AM PST The webinar will start with presentations by senior management,followed by a Q&A session.Presenters:Severin Schwan, CEO Roche GroupThomas Schinecker, CEO Roche Pharmaceuticals ad inter...
Source: Roche Investor Update - December 21, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
Thepositive CHMP opinion is based on the results of the HAVEN 6 study, which demonstrated effective bleed control and afavourable safety profile ofHemlibra in people with moderatehaemophilia A without inhibitors1Given that many people with moderatehaemophilia A may not receive prophylaxis, they may endure a worsened clinical burden with only 15% living a bleed-free life2If approved,Hemlibra, already approved for severehaemophilia A in the EU, will offer an effective and convenient prophylactic treatment option with afavourable safety profile for people with moderatehaemophilia ABasel, 16 December 2022 - Roche (SIX: RO, ROG...
Source: Roche Investor Update - December 16, 2022 Category: Pharmaceuticals Source Type: news
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
Data showcase the potential ofglofitamab andLunsumio to address diverse patient needsData presented at ASH 2022 andsimultaneouslypublished in theNew England Journal of Medicine showed thatglofitamab, given as a fixed course, induced early and durable responses in people with heavily pre-treated large B-cell lymphoma1,227-month follow-up data showedLunsumio continued to induce high and durable responses in people with relapsed or refractory follicular lymphoma, with 60% experiencing a complete response3Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that updated clinical data for its CD20xCD3 T-...
Source: Roche Investor Update - December 12, 2022 Category: Pharmaceuticals Source Type: news
Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL)1Patients receivingPolivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes, during and after fixed-duration treatment, to those receiving the current standard-of-care, withsuperiorprogression-free survival2Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy ® ...
Source: Roche Investor Update - December 12, 2022 Category: Pharmaceuticals Source Type: news
